Delta crystal form of perindopril arginine and preparation method thereof
Perindopril arginine delta crystal form of characteristic X-ray powder diffraction pattern was identified and prepared by Cu-Kα radiation. Combined with specific preparation methods, the safety hazards of dimethyl sulfoxide solvents and drug stability problems were solved, and the problem of drug stability was achieved. Improved stability and quality assurance of drugs under high temperatures and light.
Patent Information
- Application Number
- CN202410965170.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
The dimethyl sulfoxide solvent used in the preparation of the existing perindopril arginine has safety risks, and the drugs have poor physical and chemical stability during storage, transportation and treatment, and are prone to temperature, humidity and light. The effect leads to crystal form transformation or degradation, affecting the effectiveness period and quality of the drug.
Cu-Kα radiation is used to obtain the perindopril arginine delta crystal form of characteristic X-ray powder diffraction pattern, and through specific preparation methods, including mixing, acidizing extraction, concentration purification, mixing and reaction, solvent treatment, solid-liquid separation With washing and drying crystals, control dimethyl sulfoxide residues less than 0.5% to improve drug stability.
The dimethyl sulfoxide residue in perindopril arginine delta crystal form was achieved, which significantly improved the stability of the drug under high temperature and light conditions, maintained the stability of the crystal structure, and improved the quality of the drug. and medication safety.
Smart Images

Figure CN118909032A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of pharmaceutical chemical synthesis, and specifically relates to a delta crystal form of perindopril arginine as shown in the following chemical formula (I) and a preparation method thereof. Background Art
[0002] Perindopril is a powerful angiotensin converting enzyme inhibitor with a chemical formula of C 19 H 32 N 2 O 5 . As a third-generation angiotensin-converting enzyme inhibitor, perindopril can achieve maximum antihypertensive effect 6 hours after taking it, and the effect lasts for a long time. The main effect of perindopril is to dilate large and small arteries, reduce blood volume, reduce systemic vascular resistance, left ventricular filling pressure and pulmonary capillary wedge pressure. Perindopril is very well tolerated, does not cause hyperglycemia, and has no adverse effects on blood lipids. Therefore, perindopril is a very effective antihypertensive drug that can improve the function of the cardiovascular system and improve the quality of life of patients. At the same time, due to its good tolerability and benign effects on blood lipids, perindopril has become a very popular antihypertensive drug.
[0003] The arginine salt of perindopril is a relatively stable drug, which further improves the efficacy and bioavailability, making perindopril one of the important drugs for the treatment of cardiovascular diseases. It also has the advantages of stable chemical properties, good oral absorption, and obvious blood pressure regulation effect. At the same time, a large number of existing studies have provided important references and guidance for pharmaceutical companies and research and development institutions, and promoted the application and development of perindopril and its arginine salt in the medical field.
[0004] Perindopril and its pharmaceutically acceptable salts, especially its arginine salt, have unique pharmacological properties. These properties are mainly manifested in the inhibition of angiotensin I converting enzyme (or kininase II). This inhibition can prevent the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II, which is a vasoconstrictor. At the same time, it can also prevent bradykinin (a vasodilator) from being degraded into inactive peptides. These two effects make perindopril have a significant effect in the treatment of cardiovascular diseases, especially for serious diseases such as arterial hypertension and heart failure.
[0005] The arginine salt of perindopril is described in detail in European patent specification EP 1 354 873. The patent specification describes in detail the preparation method, properties and application of the arginine salt of perindopril in the treatment of various diseases. In addition, European patent specification EP 0 049 658 also describes perindopril and its preparation method and its application in the treatment of cardiovascular diseases. These patent specifications provide important theoretical support and practical guidance for the application of perindopril and its arginine salt in the medical field.
[0006]
[0007] The existing synthesis process of arginine salt of perindopril uses dimethyl sulfoxide (DMSO) solvent system. Although DMSO has good solubility, it also has certain hazards. DMSO can be quickly absorbed through the skin and distributed throughout the body, including crossing the blood-brain barrier. Excessive exposure may lead to central nervous system function inhibition; oral administration may cause digestive tract discomfort, and in severe cases may lead to ulcers; high-dose exposure may affect the normal function of the blood system and has potential bone marrow suppression; animal experiments show a certain carcinogenic risk. Therefore, it is necessary to effectively control the residual amount of DMSO. The eighth revision of "IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS" (ICH Q3C (R8)) issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use on impurities stipulates in the guideline requirements for residual solvents under impurities that the DMSO limit shall not exceed 0.5%.
[0008] Known perindopril arginine crystals exhibit poor physical and chemical stability during storage, transportation and handling. For example, they are easily affected by factors such as temperature, humidity, and light, and may undergo crystal transformation or degradation reactions, thereby affecting the shelf life and quality of the drug. Summary of the invention
[0009] In view of the problems existing in the prior art, the present invention provides a delta crystal form of perindopril arginine, characterized in that, using Cu-Kα radiation, an X-ray powder diffraction pattern represented by a diffraction angle 2θ is obtained, and characteristic peaks are displayed at 2θ of 4.137, 7.857, 11.986, 13.420, 14.109, 17.564, 20.714, 22.519, 24.475, 27.173, 28.270, and 32.438 degrees, with an error value of + / -0.2°.
[0010] In another aspect, the present invention provides a method for preparing a delta crystal form of perindopril arginine, comprising:
[0011] Step 1: Mixing materials: placing a certain amount of dichloromethane, purified water and perindopril tert-butylamine in a reaction bottle and stirring evenly; acidification extraction: controlling the temperature at 20-30°C, adding hydrochloric acid dropwise to adjust the pH to 3-4, stirring and extracting in steps, using dichloromethane to transfer the drug from the aqueous phase to the organic phase multiple times; concentration and purification: combining the organic phases, adding a small amount of purified water for washing, stirring, standing, and separating, and then vacuum reducing and concentrating the organic phase until no liquid flows out to obtain perindopril;
[0012] Step 2: mixing and reacting: adding the perindopril obtained in step 1 to purified water, starting to stir, then adding arginine, controlling the temperature at 15-30° C., and stirring to react; solvent treatment: adding the first solvent to the reaction solution, then dropping dimethyl sulfoxide, and controlling the temperature at 15-30° C.; solid-liquid separation and washing: adding the second solvent for treatment, controlling the temperature at 15-30° C., detecting the content of the residual solvent dimethyl sulfoxide, filtering and washing the wet solid; drying and crystallization: vacuum drying the wet solid to obtain a delta crystal perindopril arginine salt.
[0013] Furthermore, after adding the second solvent for treatment, the temperature is controlled at 20-25°C.
[0014] Furthermore, the first solvent used in the solvent treatment is one or more of cyclohexane, methylcyclohexane, cyclohexanone, ethylcyclohexane, decane and undecane, n-octane, dicyclohexane, toluene, xylene or cyclopentane.
[0015] Furthermore, the second solvent used in the solid-liquid separation and washing is one or more of n-heptane, methyl tert-butyl ether, n-hexane, n-decane, isooctane, ethyl tert-butyl ether, n-pentane, isohexane, heptane, dichloromethane or tetrahydrofuran.
[0016] Furthermore, the second solvent used in the solid-liquid separation and washing is n-heptane.
[0017] Furthermore, during the solid-liquid separation and washing, the second solvent is used for treatment once or multiple times.
[0018] Furthermore, the wet solid obtained after being treated with an organic solvent during the solid-liquid separation and washing is in a gravel-like state.
[0019] Furthermore, the residual amount of dimethyl sulfoxide is less than 0.5%.
[0020] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned crystal form of perindopril arginine and a pharmaceutically acceptable carrier or excipient.
[0021] Effect of the invention:
[0022] The present invention provides a novel perindopril arginine delta crystal form and a preparation method thereof. The perindopril arginine delta crystal form prepared by the method has a low residual amount of dimethyl sulfoxide (DEMO), exhibits excellent stability under high temperature and light conditions, is not prone to generating related impurities, and can maintain a stable crystal structure. This feature helps to improve drug quality and ensure drug safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the powder X-ray diffraction pattern of perindopril arginine delta 1;
[0024] Figure 2 is the powder X-ray diffraction pattern of perindopril arginine delta 2;
[0025] Figure 3 is the powder X-ray diffraction pattern of perindopril arginine delta 3;
[0026] Figure 4 is the powder X-ray diffraction pattern of perindopril arginine delta 4;
[0027] Figure 5 is the X-ray diffraction pattern of the perindopril arginine crystalline powder of Comparative Example 1;
[0028] Figure 6 is the X-ray diffraction pattern of the perindopril arginine crystalline powder of Comparative Example 2;
[0029] Figure 7 is the X-ray diffraction pattern of the perindopril arginine crystalline powder of Comparative Example 3;
[0030] Figure 8 is the X-ray diffraction pattern of the perindopril arginine crystalline powder of Comparative Example 4;
[0031] Fig. 9 This is the X-ray diffraction pattern of the perindopril arginine crystalline powder of Comparative Example 5. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the embodiments of the present application to clearly describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, rather than all the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments in the present application belong to the scope of protection of this application.
[0033] The present invention determines the powder X-ray diffraction pattern of arginine perindopril under the following experimental conditions:
[0034] Instrument model: X-ray powder diffractometer SmartLab (manufacturer: Rigaku Corporation)
[0035] Measurement conditions: CuKα1 line Monochromatic radiation, tube voltage 40 kV, tube current 40 mA, scanning range (2θ) 3°-50°, scanning step 0.01°, scanning speed 10° / min
[0036] Example 1
[0037] Preparation of δ1-crystalline perindopril arginine salt
[0038] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0039] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After the addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g n-heptane, control the temperature at 25°C, stir and slurry for 1h. Filter, visually observe that the wet solid is gravel-like, and use 23.1g n-heptane to complete the washing and transfer. After testing, the residual solvent DMSO is 22%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 hours to obtain 22.8 g of white solid, i.e., δ1 crystalline perindopril arginine salt, with a residual solvent of 0.32% DMSO.
[0040] Conclusion: The residual amount of DMSO after drying in Example 1 is 0.32%, which is relatively low.
[0041] The δ1-crystalline perindopril arginine salt of Example 1 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 1 The following Table 1-1 shows the diffraction angle of the δ1 crystalline form of perindopril arginine salt as follows:
[0042] Table 1-1
[0043]
[0044]
[0045] The stability of the δ1 crystalline perindopril arginine salt of Example 1 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the δ1 crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 1-2 below:
[0046] Table 1-2
[0047]
[0048] From the results shown in Tables 1-2 above, it can be seen that the stability of related substances and crystal forms of the δ1 crystal perindopril arginine salt of Example 1 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light irradiation, the impurities of the δ1 crystal perindopril arginine salt of Example 1 did not increase significantly over time, and the crystal structure only changed slightly, which indicates that the crystal is stable under long-term high temperature, light irradiation and accelerated experimental conditions.
[0049] Embodiment 2:
[0050] Preparation of δ2-crystalline perindopril arginine salt
[0051] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0052] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g methylcyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g n-heptane, control the temperature at 25°C, stir and slurry for 1h. Filter, visually observe that the wet solid is gravel-like, and use 23.1g n-heptane to complete the washing and transfer. After testing, the residual solvent DMSO is 21%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 h to obtain 21.7 g of a white solid, namely, δ2 crystalline perindopril arginine salt, with a residual solvent of 0.28% DMSO.
[0053] Conclusion: The residual amount of DMSO after drying in Example 2 is 0.28%, which is relatively low.
[0054] The δ2-crystalline perindopril arginine salt of Example 2 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 2 The following Table 2-1 shows the diffraction angles of the δ2 crystalline form of perindopril arginine salt as follows:
[0055] Table 2-1
[0056]
[0057]
[0058] The stability of the δ2 crystalline perindopril arginine salt of Example 2 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 2-2 below:
[0059] Table 2-2
[0060]
[0061] From the results shown in Table 2-2 above, it can be seen that the stability of related substances and crystal forms of the δ2 crystalline perindopril arginine salt of Example 2 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the δ2 crystalline perindopril arginine salt of Example 2 did not increase significantly over time, and the crystal structure only changed slightly, which indicates that the crystal is stable under long-term high temperature, light, and accelerated experimental conditions.
[0062] Embodiment 3:
[0063] Preparation of δ3 Crystalline Perindopril Arginine Salt
[0064] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0065] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After the addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g n-heptane, control the temperature at 20°C, stir and slurry for 1h. Filter, visually observe that the wet solid is gravel-like, and use 23.1g n-heptane to complete the washing and transfer. After testing, the residual solvent DMSO is 20%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 hours to obtain 23.5 g of a white solid, namely, δ3 crystalline perindopril arginine salt, with a residual solvent of 0.37% DMSO.
[0066] Conclusion: The residual amount of DMSO after drying in Example 3 is 0.37%, which is relatively low.
[0067] The δ3 crystalline perindopril arginine salt of Example 3 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 3 The following Table 3-1 shows the diffraction angles of the δ3 crystalline perindopril arginine salt as follows:
[0068] Table 3-1
[0069]
[0070]
[0071] The stability of the δ3 crystalline perindopril arginine salt of Example 3 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the δ3 crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 3-2 below:
[0072] Table 3-2
[0073]
[0074] From the results shown in Table 3-2 above, it can be seen that the stability of related substances and crystal forms of the δ3 crystalline perindopril arginine salt of Example 3 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light irradiation, the impurities of the δ3 crystalline perindopril arginine salt of Example 3 did not increase significantly over time, and the crystal structure only changed slightly, which indicates that the crystal is stable under long-term high temperature, light irradiation and accelerated experimental conditions.
[0075] Embodiment 4:
[0076] Preparation of δ4-crystalline perindopril arginine salt
[0077] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0078] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, visually observe that the obtained wet solid is gravel-like, and 23.1g n-heptane is used to complete the washing and transfer. After testing, the residual solvent DMSO is 23%. After filtration, the wet solid is placed in a vacuum drying oven, the temperature is controlled at 60-70°C, and the vacuum degree is ≤-0.08MPa and dried for 40h to obtain a white solid, i.e., 19.8g of δ4 crystalline perindopril arginine salt, and the residual solvent DMSO is 0.42%.
[0079] Conclusion: The residual amount of DMSO after drying in Example 4 is 0.42%, which is relatively low.
[0080] The δ4-crystalline perindopril arginine salt of Example 4 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 4 The following Table 4-1 shows the diffraction angles of the δ4 crystalline perindopril arginine salt as follows:
[0081] Table 4-1
[0082]
[0083]
[0084] The stability of the δ4 crystalline perindopril arginine salt of Example 4 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 4-2 below:
[0085] Table 4-2
[0086]
[0087] From the results shown in Table 4-2 above, it can be seen that the stability of related substances and crystal forms of the δ4 crystalline perindopril arginine salt of Example 4 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light irradiation, the impurities of the δ4 crystalline perindopril arginine salt of Example 4 did not increase significantly over time, and the crystal structure only changed slightly, which indicates that the crystal is stable under long-term high temperature, light irradiation, and accelerated experimental conditions.
[0088] Comparative Example 1:
[0089] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0090] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After addition, 115.0g methyl tert-butyl ether is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g methyl tert-butyl ether, control the temperature at 25°C, stir and slurry for 1h. Filter, visually observe that the obtained wet solid is in powder form, and use 23.1g methyl tert-butyl ether to complete the washing and transfer. After testing, the residual solvent DMSO is 32%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 hours to obtain 19.07 g of perindopril arginine salt as a white solid, and the residual solvent DMSO was 0.9%.
[0091] Conclusion: The residual amount of DMSO in Comparative Example 1 after drying is 0.9%, which is relatively high.
[0092] The crystalline perindopril arginine salt of Comparative Example 1 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 5 The following Table 5-1 shows the diffraction angles of the delta crystal form of perindopril arginine salt as follows:
[0093] Table 5-1
[0094] Diffraction angle (2θ°) Abundance (%) 7.780 100.0 10.519 13.1 13.230 77.7 14.020 70.5 17.439 69.3 20.037 44.9 20.494 23.5 28.118 17.3
[0095] The stability of the crystalline perindopril arginine salt of Comparative Example 1 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 5-2 below:
[0096] Table 5-2
[0097]
[0098] From the results shown in Table 5-2 above, it can be seen that the stability of related substances and crystal forms of the crystalline perindopril arginine salt of Comparative Example 1 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the crystalline perindopril arginine salt of Comparative Example 1 have a tendency to continue to degrade over time, especially after 1 to 3 months of acceleration, the impurity content is significantly increased, and the crystal structure changes greatly, which indicates that the crystal has poor stability under long-term high temperature, light and accelerated experimental conditions.
[0099] Comparative Example 2:
[0100] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0101] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After addition, 115.0g n-hexane is added to the reaction solution and stirred for 10min. Filter, and the obtained wet solid is powdery. 23.1g n-hexane is used to complete the rinsing and transfer. After testing, the residual solvent DMSO is 35%. After filtration, the wet solid is placed in a vacuum drying oven, the temperature is controlled at 60-70°C, and the vacuum degree is ≤-0.08MPa and dried for 40h to obtain 19.32g of white solid, i.e., perindopril arginine salt, and the residual solvent DMSO is 1.2%.
[0102] Conclusion: The residual amount of DMSO after drying in Comparative Example 2 is 1.2%, which is relatively high.
[0103] The crystalline perindopril arginine salt of Comparative Example 2 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 6 The following Table 6-1 shows the diffraction angles of the crystalline perindopril arginine salt as follows:
[0104] Table 6-1
[0105] Diffraction angle (2θ°) Abundance (%) 7.879 100 12.001 12.4 13.938 75.1 17.440 88.7 20.422 37.3 22.439 34.7 32.580 18.3
[0106] The stability of the crystalline perindopril arginine salt of Comparative Example 2 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 6-2 below:
[0107] Table 6-2
[0108]
[0109]
[0110] From the results shown in Table 6-2 above, it can be seen that the stability of related substances and crystal forms of the crystalline perindopril arginine salt of Comparative Example 2 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the crystalline perindopril arginine salt of Comparative Example 2 have a tendency to continue to degrade over time, especially after acceleration for 1 to 3 months, the impurity content is significantly increased, and the crystal structure changes greatly, which indicates that the crystal has poor stability under long-term high temperature, light and accelerated experimental conditions.
[0111] Comparative Example 3:
[0112] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0113] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After the addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g n-heptane, control the temperature at 0°C, stir and slurry for 1h. Filter, visually observe that the wet solid is in powder form, and use 23.1g n-heptane to complete the washing and transfer. After testing, the residual solvent DMSO is 29%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 hours to obtain 20.19 g of perindopril arginine salt as a white solid, and the residual solvent DMSO was 0.9%.
[0114] Conclusion: The residual amount of DMSO after drying in Comparative Example 3 is 0.9%, which is relatively high.
[0115] The crystalline perindopril arginine salt of Comparative Example 3 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 7 The following Table 7-1 shows the diffraction angles of the delta crystal form of perindopril arginine salt as follows:
[0116] Table 7-1
[0117] Diffraction angle (2θ°) Abundance (%) 7.762 100 12.017 22.8 13.379 83.3 17.460 79.9 19.441 35.4 23.719 18.4 27.094 20.3 32.423 19.2
[0118] The stability of the crystalline perindopril arginine salt of Comparative Example 3 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 7-2 below:
[0119] Table 7-2
[0120]
[0121] From the results shown in Table 7-2 above, it can be seen that the stability of related substances and crystal forms of the crystalline perindopril arginine salt of Comparative Example 3 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the crystalline perindopril arginine salt of Comparative Example 3 have a tendency to continue to degrade over time, especially after acceleration for 1 to 3 months, the impurity content is significantly increased, and the crystal structure changes greatly, which indicates that the crystal has poor stability under long-term high temperature, light and accelerated experimental conditions.
[0122] Comparative Example 4:
[0123] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0124] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. After the addition, 115.0g n-heptane is added to the reaction solution and stirred for 10min. Filter, add the wet solid to 230.0g n-heptane, control the temperature at 30°C, stir and slurry for 1h. Filter, visually observe that the wet solid is in powder form, and use 23.1g n-heptane to complete the washing and transfer. After testing, the residual solvent DMSO is 32%. After filtration, the wet solid was placed in a vacuum drying oven, the temperature was controlled at 60-70°C, and the vacuum degree was ≤-0.08 MPa and dried for 40 h to obtain 18.50 g of perindopril arginine salt as a white solid, and the residual solvent DMSO was 0.8%.
[0125] Conclusion: The residual amount of DMSO after drying in Comparative Example 4 is 0.8%, which is relatively high.
[0126] The crystalline perindopril arginine salt of Comparative Example 4 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Figure 8 The following Table 8-1 shows the diffraction angles of the crystalline perindopril arginine salt as follows:
[0127] Table 8-1
[0128]
[0129]
[0130] The stability of the crystalline perindopril arginine salt of Comparative Example 4 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 8-2 below:
[0131] Table 8-2
[0132]
[0133] From the results shown in Table 8-2 above, it can be seen that the stability of related substances and crystal forms of the crystalline perindopril arginine salt of Comparative Example 4 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the crystalline perindopril arginine salt of Comparative Example 4 have a tendency to continue to degrade over time, especially after acceleration for 1 to 3 months, the impurity content is significantly increased, and the crystal structure changes greatly, which indicates that the crystal has poor stability under long-term high temperature, light and accelerated experimental conditions.
[0134] Comparative Example 5:
[0135] Desalting process: 164.3g of dichloromethane, 62.0g of purified water, and 31.0g of perindopril tert-butylamine are added to the reaction bottle in sequence. Turn on the stirring, control the temperature at 20-30℃, and start to add hydrochloric acid dropwise, adjust the pH value to 3-4, and continue stirring for 30min after the addition. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, add 164.3g of dichloromethane to the aqueous phase and stir for 15min. Turn off the stirring and let it stand for 15min. Separate the liquids, combine the organic phases, add 62.0g of purified water and stir for 5min. Turn off the stirring and let it stand for 15min. Separate the liquids, control the temperature of the organic phase at 20-30℃, and the vacuum degree ≤-0.08MPa, and concentrate under reduced pressure until no liquid flows out of the condenser to obtain perindopril, which is directly used in the next step reaction.
[0136] Salt-forming process: 118.0g purified water and 25.9g perindopril are added to the reaction bottle in sequence, and stirring is started. 12.2g arginine is added to the reaction solution, and the temperature is controlled at 25°C and stirred for 1h. 161.6g cyclohexane is added to the reaction solution, the temperature is controlled at 25°C, and 227.9g dimethyl sulfoxide (DMSO) is added to the reaction solution. Filter, and visually observe that the obtained wet solid is in powder form. After testing, the residual solvent DMSO is 33%. After filtering, the wet solid is placed in a vacuum drying oven, the temperature is controlled at 60-70°C, and the vacuum degree is ≤-0.08MPa and dried for 40h to obtain 19.63g of white solid, i.e., perindopril arginine salt, and the residual solvent DMSO is 0.9%.
[0137] Conclusion: The residual amount of DMSO after drying in Comparative Example 5 is 0.9%, which is relatively high.
[0138] The crystalline perindopril arginine salt of Comparative Example 5 was obtained under the above experimental conditions, and its powder X-ray diffraction pattern is shown in Fig. 9 The following Table 9-1 shows the diffraction angles of the crystalline perindopril arginine salt as follows:
[0139] Table 9-1
[0140] Diffraction angle (2θ°) Abundance (%) 4.381 100 8.039 30.2 11.105 31.5 13.199 26.6 14.092 22.3 14.622 29.3 17.563 22.6 19.268 47.9 21.870 67.1
[0141] The stability of the crystalline perindopril arginine salt of Comparative Example 5 was studied. Specifically, the stability of the related substances and the stability of the crystalline structure of the crystalline perindopril arginine salt were investigated under different influencing factors and accelerated conditions. The results are shown in Table 9-2 below:
[0142] Table 9-2
[0143]
[0144]
[0145] From the results shown in Table 9-2 above, it can be seen that the stability of related substances and crystal forms of the crystalline perindopril arginine salt of Comparative Example 5 under different influencing factors and accelerated conditions was investigated. It can be seen that in the stability tests such as long-term high temperature and light, the impurities of the crystalline perindopril arginine salt of Comparative Example 5 showed a trend of continued degradation over time, especially after acceleration for 1 to 3 months, the impurity content increased significantly, and the crystal structure changed greatly, which indicates that the crystal has poor stability under long-term high temperature, light and accelerated experimental conditions.
[0146] The embodiments of the present application are described above in conjunction with the accompanying drawings, but the present application is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present application, ordinary technicians in this field can also make many forms without departing from the purpose of the present application and the scope of protection of the claims, all of which are within the protection of the present application.
Claims
1. A delta crystal form of perindopril arginine, characterized in that: Using Cu-Kα radiation, an X-ray powder diffraction pattern expressed as a diffraction angle 2θ was obtained, showing characteristic peaks at 2θ of 4.137, 7.857, 11.986, 13.420, 14.109, 17.564, 20.714, 22.519, 24.475, 27.173, 28.270, and 32.438 degrees, with an error value of + / - 0.2°.
2. A method for preparing the delta crystal form of perindopril arginine as claimed in claim 1, characterized in that: include: Step 1: Mixing materials: placing a certain amount of dichloromethane, purified water and perindopril tert-butylamine in a reaction bottle and stirring evenly; acidification extraction: controlling the temperature at 20-30°C, adding hydrochloric acid dropwise to adjust the pH to 3-4, stirring and extracting in steps, using dichloromethane to transfer the drug from the aqueous phase to the organic phase multiple times; concentration and purification: combining the organic phases, adding a small amount of purified water for washing, stirring, standing, and separating, and then vacuum reducing and concentrating the organic phase until no liquid flows out to obtain perindopril; Step 2: mixing and reacting: adding the perindopril obtained in step 1 to purified water, starting to stir, then adding arginine, controlling the temperature at 15-30° C., and stirring to react; solvent treatment: adding the first solvent to the reaction solution, then dropping dimethyl sulfoxide, and controlling the temperature at 15-30° C.; solid-liquid separation and washing: adding the second solvent for treatment, controlling the temperature at 15-30° C., detecting the content of the residual solvent dimethyl sulfoxide, filtering and washing the wet solid; drying and crystallization: vacuum drying the wet solid to obtain a delta crystal perindopril arginine salt.
3. The method for preparing the delta crystal form of perindopril arginine according to claim 2, characterized in that: After adding the second solvent for treatment, the temperature is controlled at 20-25°C.
4. The method for preparing the delta crystal form of perindopril arginine according to claim 3, characterized in that: The first solvent used in the solvent treatment is one or more of cyclohexane, methylcyclohexane, cyclohexanone, ethylcyclohexane, decane and undecane, n-octane, dicyclohexane, toluene, xylene or cyclopentane.
5. The method for preparing the delta crystal form of perindopril arginine according to claim 4, characterized in that: The second solvent used in the solid-liquid separation and washing is one or more of n-heptane, methyl tert-butyl ether, n-hexane, n-decane, isooctane, ethyl tert-butyl ether, n-pentane, isohexane, heptane, dichloromethane or tetrahydrofuran.
6. The method for preparing the delta crystal form of perindopril arginine according to claim 5, characterized in that: The second solvent used in the solid-liquid separation and washing is n-heptane.
7. The method for preparing the delta crystal form of perindopril arginine according to claim 6, characterized in that: During the solid-liquid separation and washing, the second solvent is used for treatment once or multiple times.
8. The method for preparing the delta crystal form of perindopril arginine according to claim 7, characterized in that: The wet solid obtained after being treated with an organic solvent during the solid-liquid separation and washing is in a gravel-like state.
9. The method for preparing the delta crystal form of perindopril arginine according to claim 8, characterized in that: The residual amount of dimethyl sulfoxide is less than 0.5%.
10. A pharmaceutical composition, characterized in that Containing the crystalline perindopril arginine according to claim 1 and a pharmaceutically acceptable carrier or excipient.
